Screener
Mineralys Therapeutics, Inc. MLYS Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Cash and cash equivalents | $112,779 | $172,921 |
| Investments | 533,281 | 483,714 |
| Prepaid and other current assets | 6,410 | 4,751 |
| Total current assets | 652,470 | 661,386 |
| Property and equipment, net | 32 | 38 |
| Other assets | 360 | 382 |
| Total assets | $652,862 | $661,806 |
| Liabilities and stockholders’ equity |
Item 1. Financial Statements
FAQ
- What is Mineralys Therapeutics, Inc.'s total current assets?
- Mineralys Therapeutics, Inc. (MLYS) reported total current assets of $652.47M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s total current assets changed year-over-year?
- Mineralys Therapeutics, Inc.'s total current assets increased by 84.1% year-over-year, from $354.51M to $652.47M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s total current assets?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s total current assets has grown at a 80.3% compound annual growth rate (CAGR), from $112.81M to $661.39M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Mineralys Therapeutics, Inc.'s total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude